{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:15:35Z","timestamp":1778051735948,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR FDN 154282"],"award-info":[{"award-number":["CIHR FDN 154282"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41375-026-02949-8","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:35:35Z","timestamp":1776404135000},"page":"906-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-5554","authenticated-orcid":false,"given":"Nathan","family":"Duong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilshad H.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geethu E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Hurren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Bok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"St-Germain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Drimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7337-4331","authenticated-orcid":false,"given":"Yongran","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Kai-Lin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dakai","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary L.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Gronda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-0148","authenticated-orcid":false,"given":"Laura","family":"Matell\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-2776","authenticated-orcid":false,"given":"Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0284-494X","authenticated-orcid":false,"given":"Stephanie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-9548","authenticated-orcid":false,"given":"Steven M.","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Raught","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max G.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Goede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Spadavecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-3899","authenticated-orcid":false,"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2949_CR1","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","volume":"168","author":"C Parham","year":"2002","unstructured":"Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R\u03b21 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699\u20135708.","journal-title":"J Immunol"},{"key":"2949_CR2","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3390\/cells9092044","volume":"9","author":"G Pastor-Fern\u00e1ndez","year":"2020","unstructured":"Pastor-Fern\u00e1ndez G, Mariblanca IR, Navarro MN. Decoding IL-23 signaling cascade for new therapeutic opportunities. Cells. 2020;9:2044.","journal-title":"Cells"},{"key":"2949_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2040622318759282","volume":"9","author":"TC Chan","year":"2018","unstructured":"Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9:111\u20139.","journal-title":"Ther Adv Chronic Dis"},{"key":"2949_CR4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.cell.2021.01.018","volume":"184","author":"CR Glassman","year":"2021","unstructured":"Glassman CR, Mathiharan YK, Jude KM, Su L, Panova O, Lupardus PJ, et al. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell. 2021;184:983\u201399.e24.","journal-title":"Cell"},{"key":"2949_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","volume":"34","author":"A Almradi","year":"2020","unstructured":"Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, et al. Clinical trials of IL-12\/IL-23 inhibitors in inflammatory bowel disease. BioDrugs. 2020;34:713\u201321.","journal-title":"BioDrugs"},{"key":"2949_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2020","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2020;22:173\u201392.","journal-title":"Am J Clin Dermatol"},{"key":"2949_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665\u201374.","journal-title":"Lancet"},{"key":"2949_CR8","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","volume":"5","author":"R Tibes","year":"2006","unstructured":"Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5:2512\u201321.","journal-title":"Mol Cancer Ther"},{"key":"2949_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1182\/blood-2007-10-119438","volume":"113","author":"SM Kornblau","year":"2009","unstructured":"Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113:154\u201364.","journal-title":"Blood"},{"key":"2949_CR10","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-09-2551","volume":"16","author":"SM Kornblau","year":"2010","unstructured":"Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res. 2010;16:1865\u201374.","journal-title":"Clin Cancer Res"},{"key":"2949_CR11","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.cell.2006.01.040","volume":"124","author":"J Moffat","year":"2006","unstructured":"Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124:1283\u201398.","journal-title":"Cell"},{"key":"2949_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2015","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2015;11:783\u201384.","journal-title":"Nat Methods"},{"key":"2949_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41556-022-00925-9","volume":"24","author":"GE Thomas","year":"2022","unstructured":"Thomas GE, Egan G, Garc\u00eda-Prat L, Botham A, Voisin V, Patel PS, et al. The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. Nat Cell Biol. 2022;24:872\u201384.","journal-title":"Nat Cell Biol"},{"key":"2949_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341.","journal-title":"Cell Stem Cell"},{"key":"2949_CR15","doi-asserted-by":"publisher","first-page":"2250348","DOI":"10.1002\/eji.202250348","volume":"54","author":"I Mezghiche","year":"2024","unstructured":"Mezghiche I, Yahia-Cherbal H, Rogge L, Bianchi E. Interleukin 23 receptor: Expression and regulation in immune cells. Eur J Immunol. 2024;54:2250348.","journal-title":"Eur J Immunol"},{"key":"2949_CR16","doi-asserted-by":"crossref","unstructured":"Roux KJ, Kim DI, Burke B, May DG. BioID: a screen for protein\u2013protein interactions. Curr Protoc Protein Sci. 2018;91:19.23.1-19.23.15.","DOI":"10.1002\/cpps.51"},{"key":"2949_CR17","doi-asserted-by":"crossref","unstructured":"Chen C, Cummings R, Mordovanakis A, Hunt AJ, Mayer M, Sept D, et al. Cytokine receptor-Eb1 interaction couples cell polarity and fate during asymmetric cell division. eLife. 2018;7:e33685.","DOI":"10.7554\/eLife.33685"},{"key":"2949_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1083\/jcb.149.4.761","volume":"149","author":"JS Tirnauer","year":"2000","unstructured":"Tirnauer JS, Bierer BE. Mini-review EB1 proteins regulate microtubule dynamics, cell polarity, and chromosome stability. J Cell Biol. 2000;149:761\u20136.","journal-title":"J Cell Biol"},{"key":"2949_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1600-0854.2005.00332.x","volume":"6","author":"DM Bryant","year":"2005","unstructured":"Bryant DM, Stow JL. Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic. 2005;6:947\u201353.","journal-title":"Traffic"},{"key":"2949_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/10799900050044769","volume":"20","author":"J Larkin","year":"2000","unstructured":"Larkin J, Johnson HM, Subramaniam PS. Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-g receptor complex following activation by IFN-g. J Interferon Cytokine Res. 2000;20:565\u201376.","journal-title":"J Interferon Cytokine Res"},{"key":"2949_CR21","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.1158\/1078-0432.CCR-08-2813","volume":"15","author":"SC Wang","year":"2009","unstructured":"Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 2009;15:6484\u201389.","journal-title":"Clin Cancer Res"},{"key":"2949_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/jcb.20451","volume":"95","author":"JJ Krolewski","year":"2005","unstructured":"Krolewski JJ. Cytokine and growth factor receptors in the nucleus: what\u2019s up with that? J Cell Biochem. 2005;95:478\u201387.","journal-title":"J Cell Biochem"},{"key":"2949_CR23","doi-asserted-by":"crossref","unstructured":"Wattanathamsan O, Pongrakhananon V. Emerging role of microtubule-associated proteins on cancer metastasis. Front Pharmacol. 2022;13:935493.","DOI":"10.3389\/fphar.2022.935493"},{"key":"2949_CR24","doi-asserted-by":"publisher","first-page":"105320","DOI":"10.1016\/j.bioorg.2021.105320","volume":"116","author":"S Khwaja","year":"2021","unstructured":"Khwaja S, Kumar K, Das R, Negi AS. Microtubule-associated proteins as targets for anticancer drug development. Bioorg Chem. 2021;116:105320.","journal-title":"Bioorg Chem"},{"key":"2949_CR25","unstructured":"Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, et al. CDK inhibitors in cancer therapy: an overview of recent development. Am J Cancer Res. 2021;11:1913\u201335."},{"key":"2949_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ccr.2014.05.006","volume":"26","author":"JM Mason","year":"2014","unstructured":"Mason JM, Lin DCC, Wei X, Che Y, Yao Y, Kiarash R, et al. Functional characterization of CFI-400945, a polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014;26:163\u201376.","journal-title":"Cancer Cell"},{"key":"2949_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41375-023-02110-9","volume":"38","author":"T Murphy","year":"2024","unstructured":"Murphy T, Mason JM, Leber B, Bray MR, Chan SM, Gupta V, et al. Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed\/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia. 2024;38:502\u201312.","journal-title":"Leukemia"},{"key":"2949_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00011-020-01339-9","volume":"69","author":"AIK Abdo","year":"2020","unstructured":"Abdo AIK, Tye GJ. Interleukin 23 and autoimmune diseases: current and possible future therapies. Inflamm Res. 2020;69:463\u201380.","journal-title":"Inflamm Res"},{"key":"2949_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","volume":"154","author":"P Foley","year":"2018","unstructured":"Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions. JAMA Dermatol. 2018;154:676\u201383.","journal-title":"JAMA Dermatol"},{"key":"2949_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMoa2308713","volume":"390","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, et al. An oral interleukin-23\u2013receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024;390:510\u201321.","journal-title":"N Engl J Med"},{"key":"2949_CR31","doi-asserted-by":"crossref","unstructured":"Fournier C, Butler MO, Sauder MB. The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: a case series and review of the literature. SAGE Open Med. Case Rep. 2023;11:2050313X231181035.","DOI":"10.1177\/2050313X231181035"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02949-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02949-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02949-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:26:28Z","timestamp":1778048788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02949-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2949"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02949-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ADS has received research funding from Takeda Pharmaceuticals and BMS and consulting fees\/honorarium from Takeda, Astra Zeneca, BMS and Novartis. ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada and the Therapy Acceleration Program of the Leukemia and Lymphoma Society. LZ is a consultant\/advisory board member for WYZE Biotech Co., Ltd. JK, MGJ, DG, and VS are employees of Interlinked Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}